JNJ vs QTI

JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.

The company exhibits critical financial weakness with a Piotroski F-Score of 1/9, indicating severe fundamental distress. Despite an extraordinary YoY revenue growth of 877.20%, the company remains deeply unprofitable with a profit margin of -111.40% and a history of massive earnings misses. Technical trends are overwhelmingly bearish, characterized by a 78.7% price collapse over the last six months. While short-term liquidity is stable, the combination of poor health scores and negative earnings progression suggests a high risk of further devaluation.